Walk into almost any corporate sustainability report published in the past three years and you will find detailed carbon accounting, careful Scope 3 boundary disclosures, and a commitment to net zero by some future date. What you will not usually find is any mention of the air inside the building in which the report was written.
This is not an oversight born of indifference. It is the product of how ESG frameworks have historically been structured — built around outputs and emissions rather than the lived environment of the people producing them. But that architecture is changing, faster than many teams realise.
The evidence base connecting indoor air quality (IAQ) to occupant health, cognitive performance, and productivity is now substantial enough to be cited in building regulations, planning frameworks, and institutional investment criteria. What was once regarded as a facilities concern — something managed at the level of HVAC maintenance schedules — is migrating upwards into corporate governance.
Consider the numbers that frame this issue:
The primary indoor pollutants of concern in commercial settings are well established: CO₂ (the proxy indicator for ventilation adequacy), fine particulate matter (PM2.5), volatile organic compounds (VOCs) from furnishings, cleaning products, and building materials, NO₂ in buildings with gas appliances or adjacent to high-traffic roads, and total volatile organic compound (TVOC) loads associated with off-gassing in newly refurbished spaces.
None of these are exotic. Most are routinely elevated in offices, schools, healthcare facilities, and commercial real estate portfolios. Most go entirely unmeasured.
Indoor air quality is not yet a mandatory line item in mainstream ESG disclosure frameworks — but the directional pressure is unmistakeable. Several convergent forces are pushing it into scope:
Both WELL (primarily adopted by corporate real estate and large occupiers) and BREEAM In-Use (the dominant UK rating for existing commercial buildings) include IAQ credits that are increasingly weighted in overall scores. As lenders and institutional investors apply green building criteria to financing terms — including the UK Green Finance Strategy's alignment with sustainable buildings — WELL and BREEAM ratings are migrating from aspiration to covenant condition.
While neither Act addresses IAQ directly, both have contributed to a regulatory culture in which the indoor environment is subject to greater scrutiny. The Environment Act 2021's new Local Air Quality Management framework increases pressure on local authorities to address AQ at a granular level, including indoor environments in their AQMA reporting obligations where evidence warrants.
The EU's Corporate Sustainability Reporting Directive — now cascading into UK-aligned frameworks through the International Sustainability Standards Board (ISSB) and the FCA's UK SDR — has a material social component. ESRS S1 (Own Workforce) requires companies to assess and disclose conditions that affect employee health and wellbeing. A building operator who cannot demonstrate that they monitor and manage indoor air quality is, increasingly, a building operator with a disclosure gap.
NHS England's Net Zero Building Standard and the broader NHS Estates decarbonisation programme have brought indoor environment quality explicitly into scope for new builds and major refurbishments. For private sector suppliers operating in healthcare facilities or letting space to NHS tenants, this standard becomes a de facto contractual benchmark.
"The question is no longer whether indoor air quality will appear in your ESG obligations — it is whether you will be measuring it before the obligation arrives, or scrambling to retrofit evidence after it does."
| Sector | Primary IAQ exposure | Current governance gap |
|---|---|---|
| Corporate & commercial real estate | CO₂, VOCs, PM2.5 in multi-let offices | No continuous monitoring; WELL credits not pursued; S1 disclosure incomplete |
| Property & development | VOC off-gassing post-refurbishment; dust during construction | Pre-occupation testing rarely conducted; no handover IAQ baseline |
| Public sector & healthcare | CO₂ in classrooms, NO₂ in clinical settings, PM2.5 near road-adjacent sites | NHS AQ obligations not matched by monitoring capacity; school programmes underfunded |
| Finance & investment | Portfolio-level IAQ risk across held assets | Due diligence processes rarely include IAQ assessment; no standard metric for comparison |
| Industrial & construction | Dust, VOCs, chemical exposures in occupied work areas | COSHH records maintained but continuous, evidenced monitoring often absent |
The organisations managing IAQ as a genuine ESG issue — rather than a facilities hygiene matter — tend to share a set of common characteristics:
The most common question we receive from sustainability and property teams when we raise indoor air quality is: "where do we start?" The honest answer is: with data you don't currently have.
A baseline IAQ survey — typically conducted over two to four weeks across a representative sample of your portfolio — will establish which sites have material exceedances, whether your HVAC is performing as designed, and what the gap is between your current position and the disclosure benchmarks your frameworks require. That baseline is the prerequisite for everything else: for remediation prioritisation, for WELL or BREEAM credit pathways, and for the S1 or equivalent disclosure that your reporting obligations will eventually demand.
The cost of baseline monitoring is, in virtually every case, a fraction of the cost of the liability it prevents — whether that liability is a lease incentive forfeited because a building cannot meet a green standard, an employee claim linked to occupational exposure, or an ESG rating downgrade triggered by a disclosure gap that a competitor has already closed.
Indoor air is not a new risk. It is an old risk that the ESG agenda has finally given a framework — and a deadline.
AuraNova conducts independent indoor air quality assessments for commercial, healthcare, and public sector clients across the UK, UAE and South Africa. Our monitoring programmes are calibrated against WHO, CIBSE, WELL and BREEAM benchmarks and produce audit-ready evidence packages suitable for ESG disclosure. Speak to our UK practice →